Overall Survival in Metastatic Breast Cancer Patients in the Third Millennium: Results of the COSMO Study-Reference-Cited by-同舟云学术

Overall Survival in Metastatic Breast Cancer Patients in the Third Millennium: Results of the COSMO Study

Published:2021-10 Issue:5 Volume:21 Page:e489-e496
ISSN:1526-8209
Container-title:Clinical Breast Cancer
language:en
Short-container-title:Clinical Breast Cancer

Author:

La Verde Nicla,Collovà Elena,Blasi Livio,Pinotti Graziella,Palumbo Raffaella,Bonotto Marta,Garrone Ornella,Brunello Antonella,Rimanti Anita,Bareggi Claudia,Zaniboni Alberto,Frassoldati Antonio,Foglietta Jennifer,Berardi Rossana,Moretti Anna,Farina Gabriella,Porcu Luca,Barni Sandro

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference14 articles.

1. Is breast cancer survival improving?;Giordano;Cancer,2004

2. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer;Chia;Cancer,2007

3. Survival of metastatic breast carcinoma patients over a 20-year period. A retrospective analysis based on individual patient data from six consecutive studies;Gennari;Cancer,2005

4. Breast cancer with synchronous metastases: trends in survival during a 14-year period;Andre;J Clin Oncol,2004

5. Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort;Gobbini;Eur J Cancer,2018

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Complete response after treatment of breast cancer with isolated liver metastasis: a case report;AME Case Reports;2024-04

2. First-line real-world treatment patterns and survival outcomes in women younger or older than 40 years with metastatic breast cancer in the real-life multicenter French ESME cohort;European Journal of Cancer;2024-01

3. Genistein and coumestrol reduce MCF-7 breast cancer cell viability and inhibit markers of preferential metastasis, bone matrix attachment and tumor-induced osteoclastogenesis;Archives of Biochemistry and Biophysics;2023-05

4. Real-world outcomes in metastatic HR+/HER2-, HER2+ and triple negative breast cancer after start of first-line therapy;Future Oncology;2023-04

5. Investigating the clinical impact of dose‐banding for weekly paclitaxel in patients with breast cancer: A retrospective and monocentric study;British Journal of Clinical Pharmacology;2023-03-20